No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: A1 - Approval loncastuximab tesirine-lpyl Sensitive : A1	loncastuximab tesirine-lpyl Sensitive: A1 - Approval loncastuximab tesirine-lpyl Sensitive : A1
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
CD19 underexpression	Diffuse Large B Cell Lymphoma	CD19 underexpression	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
BRCA mutation	Diffuse Large B Cell Lymphoma	BRCA mutation	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: D – Preclinical loncastuximab tesirine-lpyl Sensitive : D	loncastuximab tesirine-lpyl Sensitive: D – Preclinical loncastuximab tesirine-lpyl Sensitive : D
CD19 expression	Non-Hodgkin’s Lymphoma	CD19 expression	Non-Hodgkin’s Lymphoma	loncastuximab tesirine-lpyl + IGM-2323 Sensitive: D – Preclinical loncastuximab tesirine-lpyl + IGM-2323 Sensitive : D	loncastuximab tesirine-lpyl + IGM-2323 Sensitive: D – Preclinical loncastuximab tesirine-lpyl + IGM-2323 Sensitive : D
CD20 expression	Non-Hodgkin’s Lymphoma	CD20 expression	Non-Hodgkin’s Lymphoma	loncastuximab tesirine-lpyl + IGM-2323 Sensitive: D – Preclinical loncastuximab tesirine-lpyl + IGM-2323 Sensitive : D	loncastuximab tesirine-lpyl + IGM-2323 Sensitive: D – Preclinical loncastuximab tesirine-lpyl + IGM-2323 Sensitive : D
CD19 expression	Mantle Cell Lymphoma	CD19 expression	Mantle Cell Lymphoma	IKS03 Sensitive: D – Preclinical IKS03 Sensitive : D	IKS03 Sensitive: D – Preclinical IKS03 Sensitive : D
CD19 expression	Diffuse Large B Cell Lymphoma	CD19 expression	Diffuse Large B Cell Lymphoma	IKS03 Sensitive: D – Preclinical IKS03 Sensitive : D	IKS03 Sensitive: D – Preclinical IKS03 Sensitive : D
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D
MYC rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL6 rearrangement	Lymphoma	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D
CD19 positive	Non-Hodgkin’s Lymphoma	CD19 positive	Non-Hodgkin’s Lymphoma	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D

CD19-targeted antibody-drug conjugate

CD19-targeted antibody-drug conjugate

Associations(14)

Associations
(14)